A recent Phase III randomized, placebo‐controlled trial evaluated the efficacy of everolimus + endocrine therapy as adjuvant therapy for high‐risk, hormone receptor‐positive/HER2(−) breast cancer after adjuvant/neoadjuvant chemotherapy [162]. The gene discussed is NR4A1; the disease is breast carcinoma.